Advertisement
Canada markets open in 2 hours 49 minutes
  • S&P/TSX

    24,072.51
    -30.20 (-0.13%)
     
  • S&P 500

    5,751.13
    +55.19 (+0.97%)
     
  • DOW

    42,080.37
    +126.13 (+0.30%)
     
  • CAD/USD

    0.7316
    -0.0012 (-0.17%)
     
  • CRUDE OIL

    73.23
    -0.34 (-0.46%)
     
  • Bitcoin CAD

    84,777.03
    -589.48 (-0.69%)
     
  • XRP CAD

    0.73
    +0.00 (+0.17%)
     
  • GOLD FUTURES

    2,635.20
    -0.20 (-0.01%)
     
  • RUSSELL 2000

    2,194.98
    +1.89 (+0.09%)
     
  • 10-Yr Bond

    4.0330
    +0.0070 (+0.17%)
     
  • NASDAQ futures

    20,283.25
    -15.25 (-0.08%)
     
  • VOLATILITY

    21.51
    +0.09 (+0.42%)
     
  • FTSE

    8,223.28
    +32.67 (+0.40%)
     
  • NIKKEI 225

    39,277.96
    +340.42 (+0.87%)
     
  • CAD/EUR

    0.6667
    -0.0005 (-0.07%)
     

High Growth Tech Stocks To Watch In September 2024

As global markets rebound and technology stocks lead the charge, investors are keenly watching high-growth sectors for potential opportunities. With the S&P 500 Index recovering from recent losses and growth stocks outpacing value shares, it's an opportune time to explore what makes a strong tech stock in this dynamic environment.

Top 10 High Growth Tech Companies

Name

Revenue Growth

Earnings Growth

Growth Rating

TG Therapeutics

28.39%

43.54%

★★★★★★

Sarepta Therapeutics

23.58%

44.12%

★★★★★★

Seojin SystemLtd

33.61%

52.05%

★★★★★★

eWeLLLtd

26.52%

27.53%

★★★★★★

Scandion Oncology

40.71%

75.34%

★★★★★★

G1 Therapeutics

27.57%

57.75%

★★★★★★

KebNi

34.75%

86.11%

★★★★★★

Adveritas

57.98%

144.21%

★★★★★★

Travere Therapeutics

26.68%

68.80%

★★★★★★

Ascendis Pharma

39.71%

68.43%

★★★★★★

Click here to see the full list of 1289 stocks from our High Growth Tech and AI Stocks screener.

We'll examine a selection from our screener results.

Blueprint Medicines

Simply Wall St Growth Rating: ★★★★★★

Overview: Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally, with a market cap of $5.63 billion.

Operations: Blueprint Medicines generates revenue primarily through its pharmaceuticals segment, which amounted to $362.80 million. The company focuses on developing precision therapies for genomically defined cancers and blood disorders.

Blueprint Medicines showcases significant growth potential with a 67.42% annual earnings forecast, driven by robust R&D investments. The company reported $138.16 million in Q2 revenue, up from $57.57 million last year, reflecting a strategic focus on innovation and expansion within the biotech sector. Despite a net loss of $49.99 million, Blueprint's raised revenue guidance to $435-$450 million for 2024 underscores confidence in its product pipeline and market positioning amidst increasing demand for advanced therapies.

NasdaqGS:BPMC Earnings and Revenue Growth as at Sep 2024
NasdaqGS:BPMC Earnings and Revenue Growth as at Sep 2024

RingCentral

Simply Wall St Growth Rating: ★★★★☆☆

Overview: RingCentral, Inc., along with its subsidiaries, offers cloud communications, video meetings, collaboration, and contact center software-as-a-service solutions globally and has a market cap of $2.70 billion.

Operations: RingCentral generates revenue primarily from its Internet Software & Services segment, amounting to $2.31 billion. The company's offerings include cloud communications, video meetings, collaboration tools, and contact center software solutions.

RingCentral's strategic focus on innovation is evident through its robust R&D spending, which reached $79.27 million in Q2 2024. This investment supports their expanding partnership with Vodafone Business, enhancing their CCaaS and UCaaS offerings across multiple markets. Despite a net loss of $14.75 million in Q2, the company reported a revenue increase to $592.91 million from $539.31 million last year and repurchased 2,463,371 shares for $79.27 million within the quarter, reflecting confidence in long-term growth prospects amidst evolving market demands for AI-driven communication solutions.

NYSE:RNG Revenue and Expenses Breakdown as at Sep 2024
NYSE:RNG Revenue and Expenses Breakdown as at Sep 2024

King Slide Works

Simply Wall St Growth Rating: ★★★★☆☆

Overview: King Slide Works Co., Ltd., along with its subsidiaries, focuses on the research, development, design, and sale of rail kits for servers and network communication equipment in Taiwan, with a market cap of NT$112.93 billion.

Operations: King Slide Works Co., Ltd. generates revenue primarily through its subsidiaries, Chuanhu Company (NT$2.02 billion) and Chuan Yi Company (NT$6.06 billion). The company specializes in rail kits for servers and network communication equipment in Taiwan.

King Slide Works has demonstrated impressive financial performance, with Q2 2024 sales reaching TWD 2.52 billion, up from TWD 1.31 billion a year earlier. Net income nearly doubled to TWD 1.46 billion, reflecting strong operational efficiency and market demand. The company’s R&D expenses have been pivotal in driving innovation, contributing to a forecasted revenue growth of 20.6% annually, outpacing the Taiwan market's expected growth of 11.7%. Additionally, earnings are projected to grow by 11.3% per year, indicating sustained profitability amidst industry advancements in AI and tech solutions.

TWSE:2059 Revenue and Expenses Breakdown as at Sep 2024
TWSE:2059 Revenue and Expenses Breakdown as at Sep 2024

Make It Happen

Looking For Alternative Opportunities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGS:BPMC NYSE:RNG and TWSE:2059.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com